Abstract

Helicobacter pylori (H. pylori) eradication rates achieved with a proton pump inhibitor (PPI), amoxicillin and clarithromycin have recently decreased to about 75% because of the increase in clarithromycin resistance in Japan. In the present study, H. pylori resistance rates against clarithromycin, amoxicillin and metronidazole were investigated in pediatric patients and eradication rates were evaluated when tailored antibiotics regimens based on antibiotic sensitivity data were used. We isolated H. pylori endoscopically from 77 pediatric patients suffering from abdominal symptoms. The susceptibility tests of H. pylori strains to clarithromycin, amoxicillin and metronidazole were examined and eradication therapy was tailored using the appropriate antibiotics. Seventy-seven patients were treated with a mean age of 12.16 ± 3.34 years (range, 4.92-19.75) consisting of 40 males and 37 females. The average resistance rates between 1998 and 2016 to clarithromycin, amoxicillin and metronidazole were 54.5% (42 of 77), 6.5% (5 of 77) and 5.2% (4 of 77) respectively. The prevalence of clarithromycin resistance increased significantly over time to reach 88.9% by 2013-2016. Successful eradication rates using tailored antibiotic treatment was 93.8% (61 of 65). Clarithromycin-based eradication therapy rate reached 92.6% against clarithromycin-sensitive strains. Metronidazole-based initial eradication therapy also had a high successful rate (97.0%) to clarithromycin-resistant strains. Although high rates of clarithromycin resistant H. pylori reaching about 90% were observed in Japanese children, tailored eradication therapy using the appropriate antibiotic agents were highly successful. H. pylori sensitivity testing and eradication therapy with appropriate antibacterial agents may contribute to accomplishment of high initial eradication rates and consequently reducing the incidence of developing gastric cancer.

Highlights

  • Helicobacter pylori (H. pylori) is a microaerophilic Gram-negative spiral bacterial pathogen that resides in the human stomach in close association with the gastric epithelium

  • Helicobacter pylori (H. pylori) eradication rates achieved with a proton pump inhibitor (PPI), amoxicillin and clarithromycin have recently decreased to about 75% because of the increase in clarithromycin resistance in Japan

  • We investigated the H. pylori resistance rate against clarithromycin (CAM), amoxicillin (AMPC) and metronidazole (MNZ) in pediatric patients in Japan, and evaluated eradication rates with tailored antibiotics regimens that were designed based on the results of antibiotic susceptibility tests

Read more

Summary

Introduction

Helicobacter pylori (H. pylori) is a microaerophilic Gram-negative spiral bacterial pathogen that resides in the human stomach in close association with the gastric epithelium. H. pylori infection is generally acquired in childhood and typically persists for life. H. pylori infection induces chronic gastric mucosal inflammation that contributes to the development of gastric cancer. In 1994, H. pylori was declared a class I definite human carcinogen by the WHO [3] and this classification was confirmed in 2012 [4]. Eradication therapy against H. pylori infection can lead to significant improvement of gastric atrophy and may prevent the development of gastric cancer [5]-[10]. We investigated the H. pylori resistance rate against clarithromycin (CAM), amoxicillin (AMPC) and metronidazole (MNZ) in pediatric patients in Japan, and evaluated eradication rates with tailored antibiotics regimens that were designed based on the results of antibiotic susceptibility tests

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.